Avidity Biosciences gets a Hold consensus for Avidity Biosciences stock

Published on 10/16/2026 at 02:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Avidity Biosciences stock gets a Hold consensus from 16 analysts. Its USD 63.75 target accompanies USD 3.00 million revenue versus USD 0.67 million consensus.

Clinical and analyst markers

Sixteen analysts assigned a Hold consensus and an average USD 63.75 target on October 14, 2026.
Revenue reached USD 3.00 million in the second quarter of 2026 versus USD 0.67 million consensus.
The stock crossed below its USD 12.37 200-day average and reached USD 7.78 on October 7, 2026.

RNA, US05370A1088, Illustration mit AI erstellt.

Avidity Biosciences (ISIN US05370A1088) had a Hold consensus from 16 analysts and an average 12-month target of USD 63.75 on October 14, 2026, according to MarketBeat. The rating mix included 11 holds, three buys, one strong buy and one sell.

Stock3 identifies the company as Avidity Biosciences and assigns it the ISIN US05370A1088. MarketBeat identifies the primary listing as Nasdaq under ticker RNA and describes Avidity as a clinical-stage biopharmaceutical company developing antibody oligonucleotide conjugates for muscle diseases.

Three dated clinical markers

On June 18, 2026, Cantor Fitzgerald began coverage with an overweight rating and a USD 25.00 target, as reported by MarketBeat. On August 13, 2026, the company reported a second-quarter loss of USD 1.18 per share versus a USD 1.42 consensus loss, while revenue reached USD 3.00 million against USD 0.67 million expected, according to MarketBeat. On October 14, 2026, the 16-analyst Hold consensus and USD 63.75 average target became the latest marker.

What does the chart signal?

The technical picture added pressure before the latest consensus update. Avidity stock crossed below its USD 12.37 200-day moving average on October 7, 2026, traded as low as USD 7.78 and recorded volume of 411,683 shares, according to MarketBeat. The gap between the USD 12.37 average and the USD 7.78 session low shows why the rating count and the clinical pipeline remain more informative than a single target.

Pipeline remains the key variable

Avidity's antibody oligonucleotide conjugates combine antibodies with oligonucleotide medicines designed to act on RNA inside specific cells. The company directs its programs toward myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy, making clinical execution the central valuation variable.

Investor picture

The latest company-specific markers combine USD 3.00 million second-quarter revenue, a USD 63.75 consensus target and a USD 12.37 technical average. Together, they describe a company with measurable clinical and financial milestones but a wide gap between analyst valuation and recent chart levels.